-
Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
•
China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration agreement with global pharmaceutical giant Pfizer (NYSE: PFE). The partnership grants Pfizer’s affiliated companies the exclusive rights to commercialize Xacduro (durlobactam, sulbactam) in mainland China. This collaboration, set to be in effect through November 2028,…
-
Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced a licensing agreement with an undisclosed company due to commercial sensitivity and trade secret considerations. Exclusive Licensing Rights for Greater ChinaAccording to the agreement, Junshi Bio will secure exclusive licensing rights and sublicensing rights to…
-
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing an agreement with compatriot firm Sino Biopharmaceutical Ltd (HKG: 1177) for the development and commercialization of LM-108 and other potential bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) in mainland China. The specifics of the…
-
Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
•
Zai Lab Ltd (ZLAB; NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company, is set to raise capital through a secondary public offering of American Depositary Shares (ADSs) valued at USD 230 million. The offering consists of 7,843,137 ADSs, with each ADS representing ten ordinary shares of the company, priced at…
-
J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy
•
Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading player in the US medical technology sector, has announced an exclusive commercial distribution agreement with Responsive Arthroscopy Inc., an innovative medical device company specializing in sports soft tissue repair solutions. This strategic partnership is aimed at bolstering J&J MedTech’s sports medicine…
-
Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company
•
Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is poised to merge with US-based Pulmatrix, Inc. (NASDAQ: PULM). The merger will result in a Nasdaq-listed entity focused on advancing targeted protein degradation technology, a promising field in drug development. Cullgen’s uSMITE Technology PlatformCullgen leverages…
-
Triton Partners Mulls Acquisition of Germany’s Evotec SE, Shares Soar 22%
•
Private equity firm Triton Partners is reportedly contemplating the acquisition of Germany-based Evotec SE (NASDAQ: EVO), as per information from Reuters. This news catalyzed a 22% surge in Evotec’s shares on Monday, reflecting market anticipation of the potential deal. Triton’s Interest and ShareholdingTriton Partners has been in the process of…
-
Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
•
China-based Leman Biotech Co., Ltd. has reportedly completed the first closing of its Series A financing round, raising over RMB 100 million (USD 13.9 million). The round was led by Fuho Capital, with additional contributions from Jun Yi Investment and AI-driven drug R&D leader XtalPi. The funds will be directed…
-
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention to acquire 100% stakes in Xintrum Pharmaceuticals, Ltd, a biologic drug developer, for a consideration of RMB 270 million (USD 37.7 million). Upon completion of the deal, Xintrum will become a wholly owned subsidiary of…
-
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
•
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607) announced a series of partnerships with prominent pharmaceutical companies, spanning domestic and international entities. Expanding Collaborations in Pharmaceutical InnovationFrance’s Sanofi (NASDAQ: SNY) has agreed to deepen its existing partnership with SPH, initially…
-
Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials
•
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its drug candidate SY-1530. The company has decided to proactively terminate the clinical development of the BTK inhibitor as a monotherapy for recurrent/refractory mantle cell lymphoma (MCL) and other B-cell derived non-Hodgkin lymphoma (B-NHL). Despite this,…
-
Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
•
Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful completion of a Series C financing round, raising hundreds of millions of renminbi. The funding was led by Nanjing Jiangning High Tech Zone Science and Technology Entrepreneurship Investment Management Co., Ltd and Huaxing Kangping Pharmaceutical…
-
Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
•
Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing round, raising in excess of RMB100 million (USD14.04 million). The funding round was led by China Venture Capital, with participation from Betta Pharmaceuticals Co., Ltd (SHE: 300558) contributing RMB 20 million, Lenovo Capital and Incubator…
-
Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a subscription agreement between its wholly owned subsidiary, Fortvita, and Lostrancos Ventures Ltd. The agreement would have seen Lostrancos acquire a 20% stake in Fortvita for USD 20.5 million. Despite this setback, Innovent Biologics reaffirmed its…
-
Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY
•
China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD 323 million) for the third quarter of 2024, marking a 40% year-on-year (YOY) increase. The company’s competitive edge in China is attributed to its product indication expansion, extensive coverage on the National Reimbursement Drug List,…
-
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
•
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter of 2024, reporting revenues of RMB 1.271 billion (USD 178.36 million) for the first three quarters, marking a 28.87% year-on-year (YOY) increase, and a net loss of RMB 927 million (USD 130 million). The third…
-
Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%
•
Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which its wholly owned subsidiary Fortvita will sell a 20% stake to Lostrancos Ventures Ltd. for USD 20.5 million. This news has sparked market controversy, with some investors criticizing the valuation of Fortvita as being too…
-
Biogen Partners with Neomorph to Develop Molecular Glue Degraders for Alzheimer’s and Rare Diseases
•
U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop molecular glue degraders targeting key areas in Alzheimer’s, rare neurological disorders, and immunological diseases. Leveraging Neomorph’s proprietary molecular glue discovery platform, the partnership aims to enhance the identification and validation of novel small-molecule therapeutic degraders…
-
CANbridge Pharmaceuticals Scales Back US Operations, Focuses on China for R&D and Commercialization
•
CANbridge Pharmaceuticals Inc., (HKG: 1228), a China-based pharmaceutical company specializing in rare diseases, has announced recent developments regarding its operations in the United States, where the company is considering scaling down its presence. The management has decided to terminate a licensing agreement with the University of Massachusetts (UMASS) that was…
-
HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy
•
HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that it has received clearance from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for its allogeneic human induced pluripotent stem cell-derived cardiomyocytes (HiCM-188). This treatment involves administration via intramyocardial…
-
Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered its oncology pipeline through the acquisition of Modifi Biosciences, Inc., a biotechnology company specializing in direct DNA modification-enabled cancer therapeutics. This strategic move provides MSD with preclinical compounds aimed at exploiting DNA repair defects in…
-
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
•
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the bioeconomy and pharmaceutical outsourcing service industry within the region. The first plan, “Implementation Plan for Accelerating the Innovation of Synthetic Biology and Promoting the High Quality Development of the Biomanufacturing Industry in Tianjin,” aims to…
-
TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
•
TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of its Series E financing round, raising RMB 300 million (USD 42.16 million). The financing was co-led by Zhongshan Venture Capital and the AMR Action Fund. The funds raised will be directed towards the late-stage clinical…
-
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
•
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell therapies, has announced the successful completion of its Series B financing round, raising over RMB 100 million (USD 14.15 million). The financing was co-led by Orinno Capital, with additional investments from Optics Valley Industrial Investment…
-
JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
•
JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic partnership with Chongqing Genrix Bio Pharmaceutical Co., Ltd. This alliance combines Genrix Bio’s prowess in drug research and development with JD Healthcare’s extensive resource and ecological advantages in medical treatment, medication, health management, and insurance.…
-
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
•
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A financing last week. Previously operating as Hercules CM Newco Inc., the company was established by a consortium of investors including Bain Capital Life Sciences, RTW Investments, Atlas Venture, and Lyra Capital. The pipeline of Kailera…
-
Cassava Sciences to Pay Over USD 40 Million to Settle SEC Charges Over Alzheimer’s Drug Claims
•
The US Securities and Exchange Commission (SEC) has announced that US-based biotech firm Cassava Sciences Inc., along with its founder and former CEO Remi Barbier, and a former vice-president of neuroscience, have consented to pay in excess of USD 40 million to settle allegations of misleading statements concerning the efficacy…
-
Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies
•
Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma Group (China) Co., Ltd. As part of the agreement, Genor Biopharma will acquire EOC Pharma through a share exchange, resulting in a reverse takeover. The company will change its name to “Edding Genor Group Holdings…
-
Legend Biotech Corporation to Establish Advanced R&D Center in Philadelphia for Next-Generation Cell Therapies
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading chimeric antigen receptor (CAR) T cell therapy specialist based in China, has announced plans to establish a state-of-the-art research and development center in Philadelphia, Pennsylvania. The new 31,000 sq. ft. facility, expected to open in the third quarter of 2025, will focus on…
-
Bayer AG Launches New Life Sciences Incubator in Shanghai to Boost Biotech Ecosystem
•
Bayer AG (ETR: BAYN, FRA: BAYN, OTCMKTS: BAYRY), a leading German life sciences company, announced last week the opening of a new life sciences incubator in Shanghai, named Bayer Co.Lab Shanghai. The incubator is located in the Shanghai Innovation (SH-INNO) Park within the Zhanghiang biopharma cluster and is part of…
-
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
•
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has reportedly secured over RMB 100 million in a Series B financing round. The funding was provided by multiple family offices. Established in 2018, Whittilong Pharma specializes in the research and development of a diverse range…
-
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
•
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the first half of the year 2024. The company reported revenues of RMB 206 million for the period, a decrease of 41.4% year-on-year (YOY). All revenues were attributed to the direct sales of its PD-L1 monoclonal…
-
Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals
•
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of a RMB 172 million collaboration payment from Allist Pharmaceuticals Co., Ltd, a fellow Chinese pharmaceutical company. This payment includes a RMB 150 million upfront fee and a RMB 22.79 million R&D compensation. The payment stems…
-
Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China, has entered into a licensing agreement with fellow Chinese firm Nanjing JSIAMA Biopharmaceutical Co., Ltd. This deal grants Junshi the rights to research and develop, manufacture, file for regulatory approval, commercialize, and hold other interests…
-
2seventy bio and BMS Discontinue Phase III Trial for Multiple Myeloma Therapy Abecma
•
2seventy bio Inc. (NASDAQ: TSVT), a U.S.-based biotechnology company partnered with Bristol-Myers Squibb (BMS, NYSE: BMY) on the development of the chimeric antigen receptor (CAR) T-cell therapy Abecma (idecabtagene vicleucel; ide-cel), has announced the discontinuation of enrollment in a Phase III clinical trial. The trial, known as KarMMa-9, was investigating…
-
AimingMed Technologies Partners with RekeyMed to Advance Biotech and Organoid Innovations
•
Hangzhou AimingMed Technologies Co., Ltd., a leading organoid specialist based in China, has entered into a strategic partnership with RekeyMed Technology Co., Ltd, a company focused on regenerative medicine biomaterials. The collaboration aims to leverage the complementary strengths of both entities to foster the integration and innovative application of modern…
-
BeiGene’s Tislelizumab Receives Israeli Nod for Oesophageal Cancer Treatment
•
China-based biotech firm BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has been granted market approval in Israel for its programmed death-1 (PD-1) inhibitor, Tevimbra (tislelizumab). The Israeli Ministry of Health has approved Tevimbra for use as a monotherapy second-line treatment for adult patients with unresectable or metastatic oesophageal squamous…
-
ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs
•
ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined hands with Universiti Kebangsaan Malaysia (UKM) and Pharma Medical Sdn Bhd (PMSB) from Malaysia to ink a strategic cooperation framework agreement aimed at developing innovative drugs. Financial specifics of the agreement have not been disclosed.…
-
Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a strategic partnership between its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), and Haier Biomedical. The collaboration will focus on the integration of digitalization, automation, and artificial intelligence (AI) to enhance the digital and…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
-
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
•
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with two domestic biotechnology companies: Lakeshore Biotechnology, a cell and gene therapy (CGT) focused biotech, and Porton Pharma Solutions, Ltd., a CGT contract research organization (CRO) and contract development and manufacturing organization (CDMO). In July, Itcure…
-
ImmuneOnco Receives Second Payment from Instil Bio, Highlighting Ongoing Licensing Deal
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the receipt of a further payment of USD 5 million from its U.S. partner Instil Bio Inc (NASDAQ: TIL), following an initial USD 10 million payment made last month. These payments are part of a licensing agreement executed in August 2024,…
-
Beijing Centergate Technologies and Bestcomm Pharmaceutical Form Strategic Partnership in Multiple Medical Fields
•
Beijing Centergate Technologies (Holding) Co., Ltd (CENTEK, SHE: 000931), a pharmaceutical manufacturing company in China, has entered into a strategic partnership with Bestcomm Pharmaceutical Co., Ltd. The collaboration aims to leverage their combined expertise in various therapeutic areas, including cardiovascular, anesthesia, neurological, gynecological, digestive, skin, and respiratory medicine. Financial details…
-
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
•
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200 million (USD 28 million) in a Series B+ financing round. This follows a Series B funding of RMB 100 million (USD 14 million) in May, bringing the total funds raised to RMB 350 million (USD…
-
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
•
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1…
-
Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region
•
SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with fellow Chinese firm Jacobio Pharma (HKG: 1167), securing rights to Jacobio’s KRAS G12C inhibitor glecirasib and SHP2 inhibitor JAB-3312 for research, development, manufacturing, regulatory filings, and commercialization in Greater China. The agreement encompasses mainland China,…
-
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
•
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its financial report for the first half of 2024, showcasing a revenue of RMB 204 million. This substantial growth is attributed to the rapid adoption of sunvozertinib, a cutting-edge epidermal growth factor receptor (EGFR) inhibitor, which…
-
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
•
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for…
-
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
•
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked…
-
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
•
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has announced its interim results for 2024 along with significant business updates. The company reported a robust year-over-year (YOY) growth in total revenue, which stood at RMB 3,952.3 million, marking…
-
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
•
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million,…
-
Luye Pharma’s Subsidiary Boan Bio Reports 2024H1 Revenue Growth and First Full Year of Profitability
•
Luye Pharma Group, a Chinese pharmaceutical company listed in Hong Kong (HKG: 2186), has announced its 2024H1 financial report through its controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The report reveals a significant year-on-year (YOY) increase in total revenues, which stood at RMB 363 million, a rise of…
-
BeiGene Positions for Global Growth with Strong Half-Year Results and R&D Investment
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) reported robust second-quarter 2024 results, highlighting significant corporate advancements that position the company for future global expansion. For the first half of 2024, BeiGene achieved total operating revenue of USD 1.6808 billion, reflecting a 61.1% year-on-year (YOY) increase. Product revenue surged by 73.0%…
-
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
•
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange (SHE: 002294), has entered into a licensing agreement with fellow Chinese firm YolTech Therapeutics. The agreement grants Salubris exclusive rights to research and development, regulatory filings, manufacturing, and commercial sales of YOLT-101 in mainland China.…
-
Shanghai Henlius Biotech Reports 9.8% YOY Revenue Growth and Continued Profitability in 2024H1 Financial Report
•
Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2696), has reported its financial results for the first half of 2024, with a 9.8% year-on-year (YOY) increase in revenue, amounting to RMB 2.7461 billion. The company has sustained profitability, building…
-
Innovent Biologics’ President Liu Yongjun Resigns, CEO De-Chao Micheal Yu Takes R&D Reins
•
Innovent Biologics Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has reportedly seen the resignation and retirement of its president, Liu Yongjun. The company’s research and development initiatives are now under the leadership of Innovent’s founder, chairman, and CEO, De-Chao…
-
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
•
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital fund Versant Ventures to launch Borealis Biosciences, a cutting-edge biotech firm dedicated to pioneering next-generation RNA medicines for kidney diseases. Borealis emerges from incubation with a substantial USD 150 million in Series A financing, bolstered…
-
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim results for the first half of the year, setting a new revenue record with a staggering 477% year-on-year (YOY) increase, reaching RMB 824 million (USD 115.4 million). The lion’s share of this revenue came from…
-
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
•
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was spearheaded by Lynx Financial, a Shanghai-based fund with a dedicated focus on healthcare and life sciences, and was supported by…
-
Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion
•
HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was led by Shanghai-based Lynx Financial, a fund with a dedicated focus on healthcare and life sciences, and was supported by contributions…
-
Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring
•
Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans to lay off approximately 400 employees as part of a corporate restructuring, citing a general industry slowdown in early R&D activity. During the company’s Q2 2024 earnings call, CEO Christian Wojczewski attributed the below-target revenue…
-
Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment
•
Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s August 9 decision to reject its New Drug Application (NDA) for midomafetamine (MDMA) as a treatment for post-traumatic stress disorder (PTSD) in adults. This ruling is seen as a pivotal moment for the emerging psychedelics…
-
CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to locally manufacture its Gavreto (pralsetinib tablets, 100mg), transitioning from overseas supply. Domestic production is anticipated to begin by late this year or early next year, following the approval of the 300mg…
-
Sichuan Huiyu Pharmaceutical’s Chairman Ding Zhao Faces CSRC Investigation for Short-Term Stock Trading
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a Chinese pharmaceutical company, has disclosed that its Chairman and General Manager, Ding Zhao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading of the company’s shares. The matter is a personal inquiry into Mr. Ding Zhao and…
-
Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion of the first phase of a significant project in Côte d’Ivoire, West Africa. Upon full completion, the project is set to produce 5 billion drug units per year and will feature a warehouse facility capable…
-
Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership
•
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a biotechnology firm based in China, has formalized a partnership with the University of Science, Malaysia (USM). The collaboration aims to enhance academic exchange and scientific translation efforts, among other initiatives. Financial details of the agreement were not disclosed. This strategic partnership builds…
-
Shanghai Pharmaceuticals’ SH-INNO Incubator to Drive Biopharmaceutical Innovation and Collaboration
•
Shanghai Pharmaceuticals (SPH;HKG: 2607; SHA: 601607) has launched the “SH-INNO incubator,” a collaborative initiative with premier academic institutions and leading scientific research organizations. The incubator is designed to dismantle conventional silos and foster interdisciplinary collaboration among professionals, scholars, corporations, and financiers across the spectrum of “industry, academia, research, medicine, and…
-
Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
•
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S. biotech firm, have announced their intention to enter into a research collaboration aimed at developing novel molecular glue degraders for neurodegenerative diseases and oncology. Eisai will leverage SEED’s expertise in targeted protein degradation (TPD) to…
-
Bristol-Myers Squibb Terminates Partnership with Agenus on TIGIT/CD96 Bispecific Antibody
•
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its decision to end its collaboration with Agenus Inc. (NASDAQ: AGEN) regarding the development of the TIGIT/CD96-targeted bispecific antibody BMS-986442 (AGEN1777). This move follows an initial decision to advance the antibody to Phase II trials earlier this year, which resulted…
-
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
•
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition of Cerevel Therapeutics (Nasdaq: CERE), a biotech company based in Cambridge, Massachusetts. AbbVie will pay $45.00 per share for Cerevel, totaling an approximate acquisition value of $8.7 billion. The transaction, initially announced in December 2023,…
-
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
•
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a definitive merger agreement to acquire US-based biotechnology firm Jnana Therapeutics Inc. Upon completion of the deal, Jnana will become a wholly owned subsidiary of Otsuka, with the transaction valued at $800 million in upfront payment…
-
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property…
-
Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline
•
Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful completion of its first round of financing, with the specific amount remaining undisclosed. The round was led by Boehringer Ingelheim Venture Fund and Temasek, with participation from Lenovo Capital and Incubator Group, Fosun Health, and…
-
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
•
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its US partner VBI Vaccines Inc. (OTCMKTS: VBIVQ) has commenced bankruptcy reorganization proceedings. Brii Bio has a history of licensing agreements with VBI, securing exclusive global rights to BRII-179 and Asia-Pacific rights to PreHevbri (excluding Japan)…
-
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with Flagship Pioneering, a biotech company based in Cambridge, Massachusetts, known for its role as a bioplatform for innovation across a diverse portfolio of over 40 companies. The collaboration will see an initial joint funding of…
-
Livzon Pharmaceutical Group to Establish Joint Venture with PT Kalbe Farma in Indonesia
•
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced plans to form a joint venture (JV) with Indonesia’s leading pharmaceutical company, PT Kalbe Farma, TBK. The JV, with a registered capital valued at approximately RMB 582 million, will focus on the manufacturing of active pharmaceutical ingredients (APIs) in Southeast Asia.…
-
RemeGen Scales Back Private Placement to Fund New Drug R&D
•
RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan, reducing the funds raised from the initially disclosed RMB 2.55 billion in June to RMB 1.953 billion. The capital will be directed towards the research and development of new drugs, bolstering the company’s pipeline which…
-
BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration of its flagship facility in Hopewell, New Jersey, located within the Princeton West Innovation Campus. The establishment of BeiGene’s USD 800 million plant represents the successful conclusion of a three-year expansion initiative aimed at enhancing…
-
Rona Therapeutics Secures USD 35 Million in Series A+ Round to Advance Nucleic Acid Therapies
•
Rona Therapeutics, a Shanghai-based nucleic acid drug developer, has secured USD 35 million in a Series A+ financing round led by LongRiver Investments. The funding round also saw participation from Zhaode Investment, Zhongqi Capital, BioTrack Capital, and Lilly Asia Ventures. The company plans to utilize the proceeds to accelerate its…
-
China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing
•
China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome Editing Research, establishing a framework to regulate such activities and ensure their responsible development. The guidelines place a stringent prohibition on germline editing, which involves genetic modifications that could be passed down to future generations.…
-
CR Boya Bio-Pharmaceutical’s Strategic Foray: Acquiring Green Cross HK for $250M to Expand Biopharma Dominance
•
In a significant development for the biopharmaceutical industry, China Resources Medical Holdings Company Limited and its subsidiary, CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294), have entered into a strategic partnership and equity transfer agreement with GC Corp. The agreement facilitates CR Boya’s acquisition of a 100% stake in Green…
-
Jiangsu Hengrui Medicine Faces FDA Setback with Warning Letter for Quality Control Issues
•
Jiangsu Hengrui Medicine (SHA: 600276), a prominent player in China’s pharmaceutical industry, has received a warning letter from the US Food and Drug Administration (FDA), following a Form 483 issued earlier this year in June. The FDA’s notice highlights two principal deficiencies at Hengrui’s facility: the company’s quality control unit…
-
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
•
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy, has reportedly drawn the attention of a potential acquirer. This development sent Legend’s stock price climbing over 12% in a single day, as reported by the news platform Street Insider. The company has allegedly…
-
Quantum Hi-Tech Partners with East China Normal University to Establish Advanced Drug Research Lab
•
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), has entered into a strategic partnership with Shanghai’s East China Normal University (ECNU). The collaboration aims to establish a state-of-the-art joint laboratory dedicated to advancing research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDCs). Furthermore, the…
-
Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure
•
Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its programmed death-ligand 1 (PD-L1) inhibitor, envafolimab, following disappointing results from a clinical trial. The company had obtained the rights to develop this molecule for soft-tissue sarcomas in North America through a 2019 agreement with China’s…
-
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
•
A number of healthcare companies are seeking to capitalize on the recovering market conditions by filing for initial public offerings (IPOs) on the Hong Kong Stock Exchange (HKEX), a venue that has been gaining traction among life sciences companies for their public listings. According to the HKEX website, recent IPO…
-
Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition
•
Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an asset acquisition agreement with South Korean biopharmaceutical company Celltrion (KRX: 068270). The deal focuses on 14 branded products across various pan-Asia countries and regions, as well as the Marketing Authorization Holder (MAH) rights for these…
-
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised to acquire a 31.161% stake in fellow Chinese firm Nanjing Nanda Pharmaceutical Co., Ltd for a consideration of RMB 149.57 million (USD 20.6 million). Aidea had previously secured a 19.9646% stake in Nanda Pharma in…
-
Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market
•
Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful completion of a private placement of 7,446,889 shares at a price of RMB 26.61 per share. The shares will be listed on the Science and Technology Innovation Board (STAR), which is hosted by the Shanghai…
-
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696) private. According to a stock exchange announcement from the China-based firm, Fosun currently holds 323.7 million shares of Henlius, representing 59.56% of the company’s total shares.…
-
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy. THDBH120, which is being developed to treat type 2 diabetes…
-
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of a 6.01% stake in its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), through bulk trading. The transaction raised INR 7.541 billion (USD 90 million) pre-tax, or approximately USD 211 million pre-tax. Following the completion of…
-
Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced the decision to wind down two of its subsidiaries, Zhejiang Raybow Life Science Technology Co., Ltd and Raybow Europe Incorporated ApS. This strategic move aims to optimize resource allocation, reduce management costs, and enhance operational…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
•
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term loan credit from the International Finance Corporation (IFC), with the funds designated for the construction of manufacturing facilities and the development of overseas business. This development signifies that 3SBio, the first Chinese biopharmaceutical enterprise to…
-
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
•
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an option agreement with China-based Ascentage Pharma (HKG: 6855), securing exclusive development and commercialization rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in markets outside of China, Hong Kong, Macau, Taiwan, and Russia. The…
-
Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has entered into a licensing agreement with fellow pharmaceutical company Livzon Pharmaceutical Group Inc. (HKG: 1513) for the development and commercialization of fadanafil, a Category 1 chemical compound. Under the terms of the agreement,…
-
CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto
•
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to begin local manufacturing of Gavreto (pralsetinib tablets, 300mg), moving away from overseas supply. The company anticipates that domestic production will start by the end…
-
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership with Beijing Highthink Pharmaceutical Technology Service Co., Ltd. The collaboration is aimed at providing Contract Research Organization (CRO) services, specifically to support a clinical study for Apeloa’s generic version of semaglutide. Under the terms of…
-
Zai Lab’s Global R&D Leadership Transition: Dr. Harald Reinhart to Retire, Dr. Rafael Amado Expands Role
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has announced the upcoming retirement of Harald Reinhart, M.D., who serves as the President and Head of Global Development for Neuroscience, Autoimmune, and Infectious Diseases (NSAiID). Dr. Reinhart’s tenure will conclude on June 30th, 2024. In…
-
Johnson & Johnson to Acquire Biotechnology Firm Yellow Jersey for $1.25 Billion
•
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has entered into a definitive agreement with RTW Biotech Opportunities, a U.S. investment fund, for the acquisition of biotechnology firm Yellow Jersey. Yellow Jersey, a subsidiary of Swiss-based Numab, was previously acquired by RTW in 2021. The cash transaction, valued…
-
Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody
•
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing agreement with Summit Therapeutics Inc. (NASDAQ: SMMT) for ivonescimab, Akeso’s bispecific antibody (BsAb) that targets PD-1 and VEGF. The original agreement, valued at a potential USD 5 billion, was signed in December 2022 and granted…
-
Lucy Therapeutics Boosts CNS Disease Research with USD 12.5 Million in Additional Financing
•
Lucy Therapeutics Inc., a U.S.-based developer of small-molecule drugs for central nervous system (CNS) diseases, has raised an additional USD 12.5 million in financing. The company is jointly incubated by China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873). Existing investors Engine Ventures and Safar Partners spearheaded the funding…
-
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
•
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into a strategic partnership and licensing agreement with Synthego Corporation, a U.S.-based leading provider of CRISPR solutions for cell and gene therapy development. The agreement grants Synthego access to Huida’s high-fidelity Cas12 CRISPR nuclease (hfCas12Max), strengthening…
-
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
•
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) is planning to fully acquire its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696). This strategic move comes as Henlius, a Hong Kong-listed company, has suspended its shares from trading…
-
IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration
•
IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in China, has announced the signing of a non-binding Memorandum of Understanding (MoU) with a fellow Chinese IVD company, which is yet to be named. The MoU outlines the intention to explore potential collaboration opportunities, including…
-
Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation of an initial public offering (IPO) on Shanghai’s Sci-Tech Innovation Board (STAR) for its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm). Xuanzhu Biopharm, which concentrates on therapeutic areas such as oncology, metabolism, anti-infection, and digestion,…
-
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
•
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in Jiangsu province to establish a new supply center. The German multinational pharmaceutical company will invest RMB 600 million (USD 83 million) in the initial phase of the project, with the facility expected to become operational…
-
GL Capital and SciClone Pharmaceuticals Agree to Privatization and Delisting
•
GL Capital and SciClone Pharmaceuticals Inc (HKG: 6600) have jointly announced an agreement to privatize the Chinese firm and delist it from the Hong Kong Stock Exchange. SciClone, an integrated biopharmaceutical company, is engaged in both product development and commercialization with a focus on oncology and severe infections. The company’s…
-
Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement
•
China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement with US-based cell-engineering company MaxCyte Inc., (NASDAQ: MXCT). The agreement grants Legend Bio a non-exclusive worldwide license to leverage MaxCyte’s Flow Electroporation technology and ExPERT platform. This access will facilitate Legend Bio’s research, clinical development,…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced the revision of a cooperation and licensing agreement initially signed with Palleon Pharmaceuticals Inc. in June 2022. The original agreement was centered around the development of a bifunctional anti-HER2 antibody-sialidase fusion protein and a second…
-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Pharmaron to Sell Proteologix Stake in Upcoming Johnson & Johnson Acquisition
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced the sale of its 10.21% stake in Proteologix, a US-based specialist in immune-mediated diseases. The acquisition of Proteologix is set to be completed by healthcare giant Johnson & Johnson (J&J; NYSE:…
-
Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO
•
Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic preparations for the treatment of cancer and autoimmune diseases, has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 34,151,800 shares priced at HKD 13.5 per share, resulting…
-
Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China
•
Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion of its clinical partnership with Shanghai East Hospital, a Class 3A general hospital in China. This strategic collaboration aims to address the increasing demand for clinical studies within the country. The two entities initially collaborated…
-
Novartis Shakes Up Executive Suite with Appointments and Transitions
•
The president of Novartis (NYSE: NVS)’ International Business Unit has this week declared a series of significant personnel changes. Ingrid Zhang, currently serving as the China president for the Swiss pharmaceutical giant, has been appointed as the Chief Business Officer (CCO) of Novartis International Business Unit. She will lead the…
-
Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China
•
Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a partnership with compatriot firm Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) for the development and commercialization of its Category biologic product, QX004N. QX004N is an in-house developed monoclonal antibody (mAb) that specifically binds to IL-23…
-
Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li Yan, its former director and president, is currently under investigation for alleged corruption, embezzlement, bribery, and receipt of bribes as a non-state employee during the company’s business operations from 2019 to 2022. Li Yan, an…
-
Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval
•
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, which received approval in August 2023 for the treatment of EGFR Exon20ins mutated non-small cell lung cancer in China, has achieved sales of RMB 91.29 million (USD…
-
RemeGen’s Q1 2024 Revenues Surge 96.41% YOY, R&D Spending Outpaces Income
•
China-based pharmaceutical company RemeGen (HKG: 9995) has reported its financial results for the first quarter of 2024, with revenues reaching RMB 330 million (USD 45.54 million) for the three-month period, marking a significant increase of 96.41% year-on-year (YOY). However, the company recorded net losses of RMB 349 million (USD 48.2…
-
Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd., has successfully raised RMB 300 million (USD 41.4 million) in a Series B+ financing round. The funding round was led by Shenzhen Capital Group, with participation from Qianhai Ark Asset Management…
-
GenScript Biotech Corporation Reports 34.2% YOY Revenue Growth in 2023 Financial Results
•
China-based GenScript Biotech Corporation (HKG: 1548) has announced its financial results for 2023, reporting revenues of USD 839.5 million for the year, marking a 34.2% year-on-year (YOY) increase. External revenues from non-cell therapy business reached USD 554.5 million, up 8.9% YOY, while cell therapy sales soared to USD 285 million,…
-
Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership with the University of Michigan in the United States. Financial details of the collaboration remain undisclosed. The partnership will focus on developing an innovative delivery system for glucagon-like peptide-1 (GLP-1) drug targets, with the University…
-
Vazyme Partners with Yufang Medical to Boost Alzheimer’s Blood Test Sales Online
•
Vazyme Biotech Co., Ltd (SHA: 688105), based in China, has entered into a strategic partnership with Shanghai Yufang Medical Technology (Group) Co., Ltd to enhance their collaboration in the screening and testing sector. Under the terms of the agreement, the two companies will leverage their respective strengths to jointly promote…
-
Apeloa Pharmaceutical Partners with Heze Pharmaceutical for Semaglutide Biosimilar Development
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a prominent player in the Chinese pharmaceutical industry, has entered into a strategic partnership with Zhejiang Heze Pharmaceutical Technology Co., Ltd to co-develop a semaglutide biosimilar. While the financial terms of the agreement were not disclosed, the collaboration will encompass joint research and development…
-
Arnatar Therapeutics Secures $50 Million in Series A Funding to Expand into China
•
US-based biotechnology company Arnatar Therapeutics has successfully closed a $50 million Series A financing round, marking a significant step in the firm’s expansion plans into the Chinese market. The funding round, co-led by 3E Bioventures and Eight Roads, attracted substantial Chinese investment, highlighting the growing interest in innovative biotech solutions…
-
Transcenta Holdings Ltd Collaborates with Agilent Technologies on Companion Diagnostic for Osemitamab
•
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced a strategic agreement with Agilent Technologies to co-develop Claudin18.2 companion diagnostic reagents, marking a significant step in the global development of osemitamab combined with nivolumab plus chemotherapy for first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ)…
-
Sino Biopharmaceutical Partners with Boehringer Ingelheim to Bring Innovative Cancer Therapies to China
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a strategic partnership with Germany’s Boehringer Ingelheim (BI) to introduce BI’s innovative cancer therapies to the mainland China market. Under the terms of the agreement, Sino Bio will provide support for the co-development and co-commercialization of several clinical-stage drugs, including brigimadlin, zongertinib, and…
-
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
•
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to influence discourse surrounding China’s biotech sector. This week, Gallagher, along with Republican Raja Krishnamoorthi, sent a letter to US Defense Secretary Lloyd Austin, inquiring about updates on a Pentagon security review of several Chinese biotechnology…
-
Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results
•
Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its financial report for 2023, showcasing a significant increase in revenues to RMB 225 million (USD 31 million), marking a year-on-year (YOY) growth of 1,347%. This substantial revenue included RMB 124 million (USD 17.1 million) from…
-
Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center
•
Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has entered into a partnership with the Chongqing Liang Jiang New Area government to establish the Danaher Western Innovation Center in the district. This new center, located adjacent to the Children’s Hospital of Chongqing Medical University,…
-
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
•
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost for key industries in the region. In the first quarter of 2024, a total of 420 major investment projects, each valued at over RMB 100 million (USD 13.8 million), were executed, culminating in a total…
-
Beijing’s Changping District and State-owned Capital Firm Launch RMB 20 Billion Healthcare Fund
•
The Changping district of Beijing municipality has reached an agreement with Beijing State-owned Capital Operation and Management Co., Ltd to establish a medical and healthcare industry fund worth RMB 20 billion (USD 2.77 billion). This Beijing-based fund will focus on pivotal sectors including innovative drugs, innovative medical devices, and emerging…
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures
•
U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based AnHeart Therapeutics Inc. in an all-stock transaction, which has received approval from the boards of both companies. The deal is contingent upon approval from AnHeart’s shareholders and is anticipated to close in the second quarter…
-
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
•
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science and biotechnology startup incubation platform; BioLabs, an international network of membership-based shared laboratory and office spaces; and MBC BioLabs, a provider of shared laboratory facilities. Recognized as a leader in DNA-encoded library (DEL) technology and…
-
Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang
•
Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to its senior management team. Sandra Zeng has been named Chief Medical Officer, and Rico Liang has been appointed as Chief Product Officer. These strategic hires are set to bolster the company’s drug development and product…
-
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
•
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license agreement with Sosei Group Corporation (TSE: 4565), a Japanese firm. This strategic partnership aims to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, targeting a novel G protein-coupled receptor (GPCR) to address the…
-
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
•
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder CBridge Capital and executive directors Luo Yongqing and He Ying not to reduce their holdings for at least six months, according to a statement submitted to the Hong Kong Stock Exchange. This pledge reflects their…
-
InnoCare Pharma Receives IND Approval in China for BCL2 Inhibitor Combo Therapy
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has announced that it has received approval for an Investigational New Drug (IND) clinical trial filing in China. The company is set to initiate a clinical trial for its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with its Bruton’s…
-
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
•
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an initial public offering (IPO) of 12,046,400 shares on the Hong Kong Stock Exchange, with a pricing range set between HKD 19.8 and HKD 20.2 per share. The company anticipates raising between HKD 239 million and…
-
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit forecast, anticipating a minimum profit of RMB 500 million (USD 72.4 million) in 2023, marking the company’s first profitable year. This forecast is attributed to the sustained sales growth of its products Hanquyou (trastuzumab injection,…
-
Zai Lab Ltd Reports 31% YOY Growth in Product Revenues and Strategic Pipeline Expansion
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has released its financial results for 2023, along with updates on product highlights and corporate developments. The company reported total product revenues of USD 266.7 million for the year, marking a 31% year-on-year growth at constant exchange rates. This…
-
BeiGene Reports Record Revenues and Rapid Growth in Q4 and Full Year 2023 with Continued Expansion
•
BeiGene (NASDAQ: BGNE), a China-based biopharmaceutical company, has presented its financial results for the fourth quarter and full year of 2023, along with key business highlights. The company reported continued rapid global growth, with record total revenues reaching USD 634 million in the fourth quarter and USD 2.5 billion for…
-
Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development
•
Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800…
-
HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors
•
HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D) Ltd will collaborate with Hox Therapeutics Ltd, a private biotech firm dedicated to developing highly targeted cancer therapies, to create inhibitors aimed at undisclosed targets. Vernalis will leverage its advanced protein science capabilities and Hit…
-
Sinovent Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization
•
Sinovent Inc., a Suzhou-based biopharmaceutical company, has announced the successful completion of a Series E financing round, raising RMB 700 million (USD 97.2 million). The round was co-led by Tencent Investment and Guoxin Investment, with additional contributions from Jinan Industrial Development Investment, Huakong Investment, Yuekai Securities, Sea of Stars Capital,…
-
Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion
•
Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical firm MorphoSys (FSE: MOR; NASDAQ: MOR) for €2.7 billion. The transaction is anticipated to finalize in the first half of 2024, pending the fulfillment of customary conditions. By acquiring MorphoSys, Novartis aims to incorporate two…
-
Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical
•
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development (R&D) collaboration and licensing agreement with fellow domestic entity Affinity Biopharmaceutical Co., Ltd. Under the terms of the agreement, Affinity grants Anglikang exclusive rights for R&D, manufacturing, and commercialization of QHL-1618, a fully water-soluble small-molecule…
-
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
•
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with South Korean firm Myung In Pharm. Under the agreement, Myung In Pharm has been granted commercialization rights to Luye’s rivastigmine twice-weekly transdermal patch (LY03013) in South Korea. The drug is indicated for the treatment of…
-
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has exercised its option to license two drug candidates discovered by HutchMed, IMG-007 and IMG-004, under the terms of a strategic partnership signed on January 11, 2021. Upon the exercise of these options and subject to…
-
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with fellow Chinese firm WinHealth Investment (HK) Ltd concerning Velphoro (sucroferric oxyhydroxide). Initially, CMS entered into a licensing agreement with WinHealth in June of the previous year, which granted WinHealth exclusive rights for regulatory filing, import,…
-
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio with the acquisition of partial commercial rights to Protagonist Therapeutics Inc.’s investigational drug rusfertide in the U.S., and full rights outside the country. The agreement entails an upfront payment of USD 300 million to the…
-
Beijing Tiantan Biological Halts Phase III Clinical Trial for CMV Immunoglobulin Citing Strategic Reasons
•
Beijing Tiantan Biological Products Co., Ltd (SHA: 600161), a biopharmaceutical firm based in China, has declared its decision to discontinue a Phase III clinical study for its intravenous injection of cytomegalovirus human immunoglobulin (pH4). The company cited prevailing market conditions and internal strategic planning as the key factors influencing this…
-
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled an impressive 2023 performance forecast following its recent listing on the Hong Kong stock exchange. The company anticipates a more than 100% surge in…
-
Manhattan BioSolutions Strikes Agreement with Biocytogen for Access to Novel Tumor Antigens
•
Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is…
-
Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China
•
Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation agreement with Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd, granting the latter exclusive market promotion rights for its recombinant human thyroid stimulating hormone (rhTSH) in the thyroid and breast surgery markets within China. The financial…
-
Shanghai Junshi Biosciences Forecasts 6.02% Revenue Growth in 2023 Driven by Commercialized Products
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China, has released its financial forecast for 2023. The company anticipates generating RMB 1.541 billion in revenues, marking a 6.02% year-on-year (YOY) increase. Junshi Biosciences’ research and development expenses for the period are estimated at RMB…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
•
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize…
-
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a strategic cooperation and licensing agreement with Jiangsu QYuns Therapeutics Co., Ltd concerning QX008N, a monoclonal antibody (mAb) that targets thymic stromal lymphopoietin (TSLP). According to the agreement, Joincare will secure exclusive rights to research and…
-
Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center
•
The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology industrial park, marking a significant step forward for the region’s bio-industry. Within this park, Hunan Norchem Pharmaceutical Co., Ltd is preparing to establish the inaugural synthetic biology research and development center in East China, reinforcing…
-
BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application
•
The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s application for bankruptcy liquidation has been accepted for review. The Hangzhou-based firm becomes the first domestic biotech company to face insolvency this year. Established in 2018, BJ Bio focused on research and development (R&D) of…
-
Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator
•
01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly established by China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607; HKG: 2607; SPH), Shanghai Biopharmaceutical Frontier Industry Innovation Center Co., Ltd, a subsidiary of SPH, and the Hong Kong Science & Technology Parks Corporation (HKSTPC).…
-
China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews
•
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation of the China Cancer Clinical Research Medical Ethics Review Mutual Recognition Consortium. This consortium aims to streamline and standardize the ethical review process for clinical research in cancer treatment across China. The founding members of…
-
Shanghai Pharmaceutical and Sino Biopharmaceutical Form Strategic Partnership for Pharmaceutical Services
•
Shanghai Pharmaceutical Co., Ltd (SPH, SHA: 601607, HKG: 2607), a leading pharmaceutical company based in China, has entered into a partnership with fellow Chinese firm Sino Biopharmaceutical Ltd (HKG: 1177). Under the agreement, Sino Bio will prioritize Shanghai Pharma as its strategic partner in the Chinese region under equal conditions,…
-
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
•
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval services and fostering high-quality development in the pharmaceutical sector. The initiatives include supporting innovative R&D, providing financial incentives, enhancing inspection and testing capabilities, improving review and approval efficiency, and aiding in product promotion and standards…
-
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for the fiscal year ending December 31, 2023. The company expects to report revenues within the range of RMB 124-126 million (USD 17.2-17.5 million), a significant increase compared to the RMB 12.8 million (USD 1.78 million)…
-
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
•
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed at fostering high-quality development in the biomedicine industry. The initiative seeks to propel Guangzhou’s biopharmaceutical sector to overcome challenges, enhance metropolitan coordination, and spearhead industry growth in the Greater Bay Area (GBA). The program extends…
-
Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline
•
Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout from Merck that specializes in targeting interleukin-15 (IL-15). Under the terms of the deal, Calypso will receive an upfront payment of USD 250 million, along with potential milestone payments totaling up to USD 175 million.…
-
Ji Xing Pharmaceuticals Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment
•
Shanghai-based Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a licensing agreement with Biogen (NASDAQ: BIIB) for the global clinical development rights to the US company’s pipeline candidate BIIB131. The terms of the deal include an undisclosed upfront payment, milestone payments, and royalties on future global sales. BIIB131 is…
-
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
•
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a research service agreement with Germany’s BioNTech (NASDAQ: BNTX). As part of the collaboration, WuXi Bio will leverage its patented technology platform to develop antibodies targeting two undisclosed targets for BioNTech, aimed at advancing…
-
Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement
•
Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its licensing agreement with US-based Coherus BioSciences Inc. (NASDAQ: CHRS) concerning the T cell immunoglobulin and ITIM domains (TIGIT) monoclonal antibody CHS-006/JS006. The original licensing deal, established in February 2021, granted Coherus exclusive rights to Junshi’s…
-
Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies
•
Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare Capital (SHC), has reportedly secured nearly RMB 200 million (approximately USD 28 million) in a Series A financing round led by Lapam Capital, with participation from SHC. The funds will be allocated to clinical and…
-
Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications
•
Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S. giant Illumina (NASDAQ: ILMN) to localize the iScan high-end chip scanners. This collaboration aims to harness their technological strengths and resources to enhance the application of genomics in precision health management, with a particular focus…
-
Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders
•
Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field…
-
Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China
•
Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares in SanReno Therapeutics, a Shanghai-based developer of kidney drugs. This move is aimed at bolstering Novartis’s kidney product portfolio in China. The financial details of the transaction have not been disclosed. SanReno Therapeutics was established…
-
Legend Biotech’s Carvykti Therapy to Include Myeloid Neoplasms Warning in Label Update
•
GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), will update the warning label for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), to account for the potential risk of myeloid neoplasms in patients…
-
China Grand Pharmaceutical to Acquire Majority Stake in Mitsubishi Tanabe’s Tianjin Subsidiary
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to acquire a 75.35% controlling stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation for a consideration of HKD 400 million (USD 51 million). This strategic move signifies CGP’s expansion into a broader range…
-
3SBio Partners with HQ Pharma to Develop and Commercialize Eltrombopag Olamine Dry Suspension
•
3SBio Inc., (HKG: 1530), a leading biopharmaceutical company based in China, has entered into a strategic partnership with domestic firm HQ Pharma to collaborate on the technical development and commercialization of HQ Pharma’s in-house developed eltrombopag olamine dry suspension. The financial details of the agreement have not been disclosed. Eltrombopag…
-
Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service agreement with domestic firm Impact Therapeutics, securing exclusive market promotion rights for Impact’s senaparib in mainland China. Under the agreement, Huadong will pay an initial fee of RMB 100 million (USD 14 million) and is…
-
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
•
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the initiation of dosing for the first patient in a clinical trial of its candidate HFK1. This investigational drug is an immunoliposome encapsulating doxorubicin, aimed at targeting various solid tumors. The trial is being conducted concurrently…
-
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
•
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange this week. The company issued 24 million shares, each priced at HKD 11.5, resulting in a net proceeds amount of HKD 194.1 million (USD 25 million). Founded…
-
Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark licensing and cooperation agreement with US pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY). The agreement focuses on Biokin’s antibody-drug conjugate (ADC) candidate, BL-B01D1, which targets EGFR and HER3. The deal was conducted specifically between…
-
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a research partnership with Evive Biotech Ltd, a subsidiary of Chinese pharmaceutical company Yifan Pharmaceutical Co., Ltd (SHE: 002019). The collaboration will utilize Nona’s antibody technology platform, Harbour Mice, to focus on the discovery of dual…
-
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China. Under the terms of the agreement, Grand Life will serve as the sole marketing promotion…
-
Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement with German pharmaceutical giant Merck KGaA for its in-house developed colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). According to the agreement, Merck will secure an exclusive license to commercialize pimicotinib in mainland China, Hong…
-
Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery
•
Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu Pharmaceutical Technology Co., Ltd, a China-based company previously established as a wholly foreign-owned enterprise (WFOE) by Hong Kong WD Pharmaceutical Co., Ltd. The financial details of the agreement have not been disclosed. This collaboration aims…
-
Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech firm Carmot Therapeutics, a specialist in anti-obesity and diabetes drugs, in a transaction valued at USD 2.7 billion with potential milestone payments of up to USD 400 million. The acquisition is expected to close in…
-
Novartis Invests USD 86.4 Million in New Radiotherapy Facility in China
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has invested over 600 million Chinese yuan (approximately USD 86.4 million) to establish a new radiotherapy production facility in China. Located in Haiyan, Zhejiang province—roughly 60 miles from Shanghai—the new plant is slated to become operational by 2026, enhancing Novartis’ capacity for local production.…
-
Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing of a licensing and supply agreement with Thailand-based Innobic. Under the terms of the deal, Innobic will support the registration and commercialization of Mabwell’s products in Thailand, a member country of the Pharmaceutical Inspection Co-operation…
-
Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments
•
China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into a cooperation framework agreement with Wuxi Gaofa Investment Development Group Co., Ltd to establish a joint venture (JV). The JV will focus on the research, development, manufacturing, and sale of golidocitinib and DZD8586, which are…
-
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma USA, is partnering with Treehill Partners, a US-based financial and deal-making advisory firm specializing in the healthcare sector. The collaboration aims to establish a jointly operated investment vehicle targeting individual clinical-stage assets. Targeting High-Potential Clinical-Stage…
-
BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule innovative drug global industrialization base in Suzhou, Jiangsu province. The 50,000 square meter facility is projected to produce 1 billion tablets/granules of solid preparations annually. State-of-the-Art Production Capabilities The plant is equipped with commercial-scale and…
-
Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes
•
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to establish a joint venture (JV) with Germany’s Eckert & Ziegler Radiopharma Projekte UG. This strategic partnership aims to combine the expertise of both companies in the field of medical isotopes. Investment and JV FormationThe joint…
-
Boehringer Ingelheim and Scottish Enterprise Co-Lead GBP 4.3M Seed Funding for Glox Therapeutics
•
Germany’s Boehringer Ingelheim, in collaboration with Scotland’s national economic development agency Scottish Enterprise, has co-led a GBP 4.3 million (USD 5.3 million) seed funding round for Scotland-based biotechnology company Glox Therapeutics. The investment will enable Glox to establish new laboratories and expand its team, bolstering its mission to develop precision…
-
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
•
It has been reported that Benjamin L. Basil, the current president and general manager of Eli Lilly (NYSE: LLY) China, will be leaving his position and the country for personal reasons. This change comes after Basil assumed the role in September 2022, succeeding Julio Gay-Ger. Background and AchievementsBasil’s tenure at…
-
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
•
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a platform for multiple companies to announce their strategic partnerships in China. Among the notable participants are Danaher (NYSE: DHR), Boehringer-Ingelheim (BI), Merck Sharp & Dohme (MSD, NYSE: MRK), Johnson & Johnson (J&J, NYSE: JNJ), BeiGene…
-
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc (AZ; NASDAQ: AZN) has signed over 30 agreements with Chinese provincial governments and other entities, marking a significant expansion in China. The agreements include substantial investments and collaborations aimed at enhancing local production, improving access…
-
Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China
•
Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration and license agreement with Shanghai-based Celest Therapeutics Co., Ltd. The partnership will see Celest manage a pilot clinical trial in mainland China for Senti’s SENTI-301A, an off-the-shelf CAR-NK cell therapy targeting GPC3-expressing tumors. Senti will…
-
Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China
•
Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading China-based pharmaceutical distribution giant, to collaborate on the Alzheimer’s disease (AD) drug Leqembi (lecanemab). The deal is potentially valued at RMB 1.5 billion (USD 205 million) and…
-
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
•
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third quarter of 2023, showcasing a significant year-on-year (YOY) increase in global sales. The company’s revenues rose by 155% to USD 40.1 million, reflecting the success of its anti-anemia drug for chronic kidney disease (CKD), Evrenzo…
-
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
•
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals
•
China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with German giant BASF SE. This collaboration aims to explore and enhance research and development of new materials for application in drug 3D printing. Financial details of the partnership have not been disclosed. Triastek utilizes a…
-
Boehringer Ingelheim Appoints Mohammed Tawil as New CEO for Greater China Region
•
Germany’s Boehringer Ingelheim (BI) has announced a leadership transition within its Greater China region, which includes mainland China, Hong Kong, and Taiwan. Dr. Pavol Dobrocky will be succeeded by Mohammed Tawil as the president and chief executive officer (CEO). Mohammed Tawil’s Background and ExperienceMohammed Tawil currently serves as the president,…
-
Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion
•
Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of its expanded manufacturing plant in Shanghai, China. The expansion, which was completed in 15 months, is set to significantly enhance the company’s manufacturing capabilities by doubling its current capacity. Shanghai Plant’s Strategic ImportanceThe firm’s China…
-
Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced a significant ten-year partnership agreement with Wuhan Hesheng Technology Co., Ltd. While the financial specifics of the deal remain undisclosed, the collaboration is poised to enhance both companies’ capabilities in the pharmaceutical sector. Collaboration Focused…
-
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company with operations in the Netherlands, the United States, and China, has formed a strategic partnership with Ingenia Therapeutics, a pre-clinical biotech with a presence in the United States and South Korea. The collaboration aims to…
-
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
•
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement with fellow Chinese firm LanssonPharm. The agreement grants Livzon exclusive rights to Lansson’s phosphodiesterase 4 (PDE4) inhibitor, LS21031, in Greater China, marking a strategic move to expand Livzon’s portfolio in the mental health space. Terms…
-
Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced an investment of USD 2 million to establish a wholly owned subsidiary, Apeloa Europe GmbH, in Germany. This strategic move is aimed at deepening the company’s globalization strategy, expanding its global market presence, and enhancing…
-
AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease
•
AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive right obtained in 2021. The acquisition was contingent upon the successful completion of pre-clinical studies on Mitokinin’s lead program, a potential first-in-class PINK1 activator for the treatment of Parkinson’s disease (PD). Details of the AcquisitionAbbVie…
-
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
•
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on the Nasdaq exchange last week. The company issued 2.5 million American depositary shares at a price of USD 23 each, resulting in a gross proceeds of USD 57.5 million. In addition, Adlai Nortye secured USD…
-
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
•
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in…
-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed. Focus on Multi-Specific TherapeuticsPanolos Bioscience is a biopharmaceutical company specializing in…
-
Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing
•
Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised over RMB 100 million (USD 13.8 million) in a pre-Series B financing round. The funds will be allocated to support product iteration and global development initiatives over the next four years, marking a significant step…
-
Everest Medicines Partners with Kezar Life Sciences to Commercialize Zetomipzomib in Asia
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a strategic collaboration and license agreement with US firm Kezar Life Sciences Inc. (NASDAQ: KZR) to develop and commercialize zetomipzomib, Kezar’s novel first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea, and Southeast Asia. This partnership aims to leverage the…
-
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
•
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises Ltd, announcing the termination of their license and collaboration agreement concerning CD47 antibody compounds and products. The agreement, initially signed on September 3, 2020, and amended on August 15, 2022, will officially end on November…
-
Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with Muscat Changming Investments LLC, leveraging business development plans and market demand in Oman and the Middle East. Joint Venture Establishment and ObjectivesThe partnership aims to establish a joint venture (JV) in the Sultanate of Oman,…
-
BRIM Biotechnology Raises $45.8 Million in Premium Share Issue for Pipeline Expansion
•
Taiwan-based BRIM Biotechnology, Inc. (TPEx 6885), a biotechnology company specializing in the development of regenerative peptides for ophthalmology and degenerative joint diseases, has announced the successful issuance of 22,500 shares at a premium of USD 2.03, raising a total of USD 45.8 million. The rights issue was fully paid on…
-
CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first half of 2023, recording revenues of RMB 21.09 million (USD 2.89 million), a decrease of 96.7% year-on-year (YOY). The contributions from China and overseas markets were RMB 17.93 million and RMB 3.16 million, respectively. The…
-
GemPharmatech Partners with Daxiang Biotech to Advance Preclinical Evaluation Models
•
Nanjing-based GemPharmatech Co., Ltd, a center for laboratory animal seed resources and a specialist in mouse models, has entered into a partnership with Daxiang Biotech, a leading domestic company in the organoid-on-a-chip field. The collaboration aims to promote the technical integration of mouse models and organoids, with the goal of…
-
Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has entered into an exclusive licensing agreement with the Affiliated Hospital of Southwest Medical University. The agreement pertains to TBM-001, a radionuclide drug conjugate (RDC) designed for early diagnosis and…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
-
Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion
•
China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to release 68 million shares priced at HKD 38.30 (USD 4.90), offering an 8.8% discount to the September 11, 2023, closing price. Morgan Stanley is acting as the agent for the placement, responsible for securing purchasers…
-
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
•
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ: TSVT) have announced plans to build on their 2022 collaboration agreement. The latest deal grants JW Therapeutics the option to develop up to two additional candidate drugs from 2seventy Bio’s product portfolio, including a T…
-
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
•
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs and drug immunotherapies, is poised to raise HKD 220 million (USD 28.4 million) through an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 11,001,200 shares at a price…
-
Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents
•
China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents, has reportedly raised over RMB 200 million (USD 27.4 million) in a Series B financing round. The investors in this round include Gongqingcheng Huayi Private Equity Fund Management, Guangfa Qianhe Investment, IDG Capital, and Shanghai…
-
Danaher Partners with Beijing’s Changping District to Accelerate Science and Technology Innovation Center
•
US-headquartered Danaher (NYSE: DHR), a Fortune 500 science and technology innovator, has entered into a partnership with the Changping District People’s Government of Beijing Municipality. The collaboration aims to jointly accelerate the construction of Danaher’s science and technology innovation center in the North and a leading synthetic biology innovation service…
-
ImmuneOnco Biopharmaceuticals Begins Trading on HKEX with Successful IPO
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) marked its debut on the Hong Kong Stock Exchange this morning, with a positive start as its share price surpassed the issuance price of RMB 18.6 per share in early trading. The initial public offering (IPO) is anticipated to raise over HKD 300…
-
Innovac Therapeutics Secures $18 Million in Pre-Series A Financing for mRNA Vaccine Development
•
Innovac Therapeutics, a Massachusetts-based mRNA vaccine developer, has announced the successful completion of its Pre-Series A financing round, raising $18 million. The funding was led by Lichen Capital, Vision Plus Capital, Couplet Health fund, TG Sino-Dragon Fund, and other investors. The proceeds from this round will be directed towards the…
